Soligenix Inc (SNGX) Stock Price, Quote & News

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology th...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 538 8200

Fax: 609 452 6467

Website: www.soligenix.com

Address:

29 Emmons Drive, Suite B-10, Princeton, United States

splendor Jul. 13 at 9:35 AM

$SNGX soon👀

0 · Reply

Stockman1985 Jul. 10 at 4:12 PM

$SNGX

0 · Reply

JK1033 Jul. 9 at 7:58 PM

$SNGX

0 · Reply

JK1033 Jul. 9 at 7:52 PM

$SNGX ok… heat-stable ThermoVax, hmmmmm…. This is not new information to the bio community, if it’s so great, why are we still waiting for MA, funding, partnership with a major pharmaceutical manufacturer? Don’t get me wrong, I’m all in, riding it until the end, whatever the outcome will be.

1 · Reply

splendor Jul. 9 at 7:40 PM

$SNGX My top two picks for 500%+ gains are $QUCY and $SNGX. Both are positioned for massive grant catalysts ahead—SNGX for its Ebola vaccine and QUCY for defense drones.

0 · Reply

NoQinyoface Jul. 9 at 5:50 PM

$SNGX are we still positive Petes about this or are we going to be a bunch of negative Nancys?

1 · Reply

splendor Jul. 9 at 5:36 PM

$SNGX Anyone reading this Gavi piece can see global organizations are practically begging for a solution to the vaccine logistics nightmare. With cold chains failing on impassable roads, the odds of funding for $SNGX’s heat-stable ThermoVax platform are higher than ever. 6$ + first target.

1 · Reply

splendor Jul. 9 at 5:18 PM

$SNGX Just published on Gavi today: "Why the fight against Ebola is a logistics challenge, not just a medical one." The article highlights a brutal reality in places like the DRC: complex software or data tracking can't fix "impassable roads" and "unreliable electricity" that destroy standard vaccine cold-chains. A medical breakthrough is useless if it spoils before arrival. This is exactly why Soligenix’s ThermoVax® platform is a structural game-changer. By making vaccines heat-stable (up to 40°C), it eliminates cold-chain dependency entirely. Global health organizations are openly admitting that logistics are the real bottleneck. $SNGX holds the exact physical solution they need for future outbreak responses. Real fundamental alignment here. $MRNA $CODX https://www.gavi.org/vaccineswork/why-fight-against-ebola-logistics-challenge-not-just-medical-one

0 · Reply

splendor Jul. 9 at 3:45 PM

$SNGX My outlook on $SNGX funding timing: Optimistic scenario is July 12-14 or July 21-24. Highly unlikely we see anything sooner, though anything is possible.

1 · Reply

BmoreBoy89 Jul. 8 at 3:28 PM

$SNGX The latest from CEPI. https://cepi.net/bundibugyo-and-100-days-mission-preparedness-readiness-and-response

2 · Reply

Soligenix to apply for vaccine development funding for Bundibugyo Ebola vaccine

Jun 8, 2026, 7:30 AM EDT - 5 weeks ago

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

May 26, 2026, 7:30 AM EDT - 6 weeks ago

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

2026-05-08T12:43:19.000Z - 2 months ago

Soligenix reports Q1 EPS (28c) vs. (97c) last year

May 8, 2026, 7:30 AM EDT - 2 months ago

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

May 8, 2026, 7:00 AM EDT - 2 months ago

Soligenix Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 2 months ago

Soligenix Earnings release: Q1 2026

2026-05-04T11:16:01.000Z - 2 months ago

Soligenix price target lowered to $1.50 from $10 at Alliance Global

2026-04-28T12:08:02.000Z - 2 months ago

Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma

Apr 28, 2026, 7:30 AM EDT - 2 months ago

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Apr 8, 2026, 7:00 AM EDT - 3 months ago

Soligenix Slides: Corporate presentation

2026-04-02T12:03:59.000Z - 3 months ago

Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial

Apr 2, 2026, 7:30 AM EDT - 3 months ago

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Mar 31, 2026, 7:30 AM EDT - 3 months ago

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

Mar 31, 2026, 7:00 AM EDT - 3 months ago

Soligenix Annual report: Q4 2025

2026-03-26T11:36:24.000Z - 3 months ago

Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease

Mar 26, 2026, 7:30 AM EDT - 3 months ago

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

Mar 26, 2026, 7:00 AM EDT - 3 months ago

Soligenix Slides: Corporate presentation

Mar 23, 2026, 7:30 AM EDT - 4 months ago

HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

Mar 19, 2026, 8:00 AM EDT - 4 months ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.

2026-03-19T11:36:43.000Z - 4 months ago

Soligenix announces HyBryte clinical summary published

Mar 19, 2026, 7:30 AM EDT - 4 months ago

Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

Mar 17, 2026, 7:00 AM EDT - 4 months ago

Soligenix Slides: Corporate presentation

2026-03-10T11:42:32.000Z - 4 months ago

Soligenix says SGX945 granted PIM designation in UK by MHRA

Mar 10, 2026, 7:30 AM EDT - 4 months ago

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

2026-02-26T13:00:59.000Z - 4 months ago

Soligenix receives positive opinion from EMA for OOD request for dusquetide

Feb 26, 2026, 7:30 AM EST - 4 months ago

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

Feb 24, 2026, 7:30 AM EST - 4 months ago

Soligenix to Present at BIO Investment & Growth Summit

Feb 12, 2026, 7:30 AM EST - 5 months ago

Soligenix Details Recent Progress and Upcoming Milestones

2025-12-18T12:41:21.000Z - 7 months ago

Soligenix’s SGX945 in Behcet’s Disease published in Rheumatology (Oxford)

Dec 18, 2025, 7:30 AM EST - 7 months ago

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

2025-12-17T12:36:34.000Z - 7 months ago

Soligenix announces results from Phase 2a trial of SGX302

Dec 17, 2025, 7:30 AM EST - 7 months ago

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Dec 3, 2025, 8:30 AM EST - 7 months ago

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

2025-11-19T12:35:43.000Z - 8 months ago

Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte

Nov 19, 2025, 7:30 AM EST - 8 months ago

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Nov 7, 2025, 7:30 AM EST - 8 months ago

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Nov 7, 2025, 7:00 AM EST - 8 months ago

Soligenix Quarterly report: Q3 2025

Oct 14, 2025, 7:30 AM EDT - 9 months ago

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

2025-10-07T11:35:32.000Z - 9 months ago

Soligenix’s HyBryte achieves safety milestone in Phase 3 T-cell lymphoma trial

Oct 7, 2025, 7:30 AM EDT - 9 months ago

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

2025-09-30T11:35:29.000Z - 10 months ago

Soligenix expands European Medical Advisory Board for CTCL

Sep 30, 2025, 7:30 AM EDT - 10 months ago

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Sep 29, 2025, 4:05 PM EDT - 10 months ago

Soligenix Announces Closing of $7.5 Million Public Offering

Sep 26, 2025, 6:33 AM EDT - 10 months ago

Soligenix Announces Pricing of $7.5 Million Public Offering

Sep 23, 2025, 7:30 AM EDT - 10 months ago

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

2025-09-19T21:05:11.000Z - 10 months ago

Soligenix files to sell 2.91M shares of common stock, 2.91M warrants

Sep 19, 2025, 8:00 AM EDT - 10 months ago

Soligenix Registration statement: Registration Filing

Sep 19, 2025, 7:00 AM EDT - 10 months ago

Soligenix Slides: Corporate Presentation

2025-09-04T11:35:46.000Z - 11 months ago

Soligenix’s ThermoVax platform shows efficacy in vaccine stability

Sep 4, 2025, 7:30 AM EDT - 11 months ago

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Sep 2, 2025, 7:30 AM EDT - 11 months ago

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-18T11:35:27.000Z - 11 months ago

Soligenix’s dusquetide granted Orphan Drug Designation in Behcet’s Disease

Aug 18, 2025, 7:30 AM EDT - 11 months ago

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Aug 14, 2025, 4:00 PM EDT - 11 months ago

Soligenix Quarterly report: Q2 2025

Aug 14, 2025, 7:30 AM EDT - 11 months ago

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

2025-08-13T22:00:32.000Z - 11 months ago

Soligenix receives FDA orphan designation for dusquetide

Aug 8, 2025, 8:30 AM EDT - 1 year ago

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Jul 8, 2025, 7:30 AM EDT - 1 year ago

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Jul 1, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Jun 6, 2025, 9:37 AM EDT - 1 year ago

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

May 9, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

May 8, 2025, 7:00 PM EDT - 1 year ago

Soligenix Quarterly report: Q1 2025

May 8, 2025, 7:00 PM EDT - 1 year ago

Soligenix Earnings release: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Soligenix Proxy statement: Proxy Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

Soligenix Proxy statement: Proxy Filing

Apr 14, 2025, 7:30 AM EDT - 1 year ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Mar 25, 2025, 8:30 AM EDT - 1 year ago

IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Mar 21, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Soligenix Annual report: Q4 2024

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Soligenix Earnings release: Q4 2024

Mar 6, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Feb 4, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at BIO CEO & Investor Conference

Jan 16, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at Upcoming Investor Conferences

Jan 14, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 1 year ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 2, 2024, 7:30 AM EST - 1 year ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Nov 19, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 15, 2024, 7:30 AM EST - 1 year ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 14, 2024, 7:15 AM EST - 1 year ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 8, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Nov 7, 2024, 7:00 PM EST - 1 year ago

Soligenix Quarterly report: Q3 2024

Nov 7, 2024, 7:00 PM EST - 1 year ago

Soligenix Earnings release: Q3 2024

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

splendor Jul. 13 at 9:35 AM

$SNGX soon👀

0 · Reply

Stockman1985 Jul. 10 at 4:12 PM

$SNGX

0 · Reply

JK1033 Jul. 9 at 7:58 PM

$SNGX

0 · Reply

JK1033 Jul. 9 at 7:52 PM

1 · Reply

splendor Jul. 9 at 7:40 PM

$SNGX My top two picks for 500%+ gains are $QUCY and $SNGX. Both are positioned for massive grant catalysts ahead—SNGX for its Ebola vaccine and QUCY for defense drones.

0 · Reply

NoQinyoface Jul. 9 at 5:50 PM

$SNGX are we still positive Petes about this or are we going to be a bunch of negative Nancys?

1 · Reply

splendor Jul. 9 at 5:36 PM

1 · Reply

splendor Jul. 9 at 5:18 PM

0 · Reply

splendor Jul. 9 at 3:45 PM

$SNGX My outlook on $SNGX funding timing: Optimistic scenario is July 12-14 or July 21-24. Highly unlikely we see anything sooner, though anything is possible.

1 · Reply

BmoreBoy89 Jul. 8 at 3:28 PM

$SNGX The latest from CEPI. https://cepi.net/bundibugyo-and-100-days-mission-preparedness-readiness-and-response

2 · Reply

BillionerOfKing Jul. 7 at 9:33 PM

$SNGX Current Stock Price: $0.38

1 · Reply

Jmiz1986 Jul. 7 at 6:43 PM

$SNGX you know how you know this is legit ? Where it doesn’t have random pumps for no reason. It’s been stabled at .39-.40 for quite sometime and just awaiting a catalyst to bring it over the hump. May we be blessed with something positive for the sake of the people in the condo mostly.

0 · Reply

Stockman1985 Jul. 7 at 3:22 AM

$SNGX

0 · Reply

Jmiz1986 Jul. 6 at 9:42 PM

$SNGX

0 · Reply

Irishihadmore Jul. 6 at 3:27 PM

$SNGX

0 · Reply

BmoreBoy89 Jul. 6 at 2:41 PM

$SNGX Still some time to add here. Don’t let the silence fool you.

1 · Reply

BmoreBoy89 Jul. 4 at 4:16 PM

$SNGX From CEO of GAVI. https://www.nature.com/articles/s44360-026-00173-3?trk=comments_comments-list_comment-text

0 · Reply

Stockman1985 Jul. 3 at 10:28 AM

https://stocktwits.com/news-articles/markets/equity/why-is-sngx-stock-up-today-soligenix-ebola-vaccine/cZggefKReAA $SNGX Getting closer

1 · Reply

Stockman1985 Jul. 2 at 8:43 PM

$SNGX very highly shorted. Any news at all and we fly.

2 · Reply

Kratos6 Jul. 2 at 8:34 PM

$SNGX no unique patents or FDA submissions in over 7 years, this thing is kaput

3 · Reply

Stockman1985 Jul. 2 at 3:00 PM

$SNGX

0 · Reply

splendor Jul. 2 at 1:33 PM

$SNGX Nature just dropped a massive piece on the Bundibugyo Ebola outbreak! Gavi & CEPI are deploying over $100M in a rapid "push-pull" funding mechanism. CEPI has $60M+ for clinicals (which SNGX already applied for! 🚀), but Gavi just opened a $40M First Response Fund specifically for manufacturing & supply security. Why is this HUGE for Soligenix? Gavi’s main focus is overcoming cold-chain logistics in the DRC. SNGX’s ThermoVax® (heat-stable tech) is literally the perfect and only logical solution for this environment. The global health architecture is throwing cash at this outbreak right now. If SNGX secures a piece of Gavi's $40M "pull" incentive on top of CEPI, this micro-cap is going to melt faces. Massive catalyst loading $MRNA $CODX https://www.gavi.org/news/media-room/unicef-and-gavi-launch-call-manufacturers-support-accelerated-access-bundibugyo?hl=en-US

2 · Reply

Market Cap	5.34M
Revenue (ttm)	0.00
Net Income (ttm)	-11.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	269,800
Avg Vol	9,031,262
Day's Range	N/A - N/A
Shares Out	14.82M
Stochastic %K	5%
Beta	1.92
Analysts	Strong Buy
Price Target	$1.75